|
Reference 1 |
||||||
|
negative |
faint |
moderate |
strong |
|||
|
Benign tumours |
7 |
0 |
0 |
0 |
||
|
Borderline serous tumours |
18 |
1 |
0 |
0 |
||
|
Serous carcinomas |
105 |
15 |
4 |
2 |
||
|
Borderline mucinous tumours |
9 |
6 |
0 |
1 |
||
|
Mucinous carcinomas |
9 |
1 |
0 |
2 |
||
|
Borderline endometrioid tumours |
1 |
0 |
0 |
0 |
||
|
Endometrioid carcinomas |
17 |
1 |
1 |
1 |
||
|
Clear cell carcinomas |
3 |
1 |
1 |
0 |
||
|
Granulosa cell tumours |
20 |
0 |
0 |
0 |
||
|
Mixed tumours |
8 |
0 |
0 |
0 |
||
|
Carcinosarcomas |
5 |
3 |
4 |
1 |
||
|
Total |
202 |
28 |
10 |
7 |
||
There was no correlation of immunoreactivity with tumour type, stage, grade or survival1.
This page last revised 28.1.2006.
©SMUHT/PW Bishop